Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Sets Out To Win Over Investors In Its First Financial Call

This article was originally published in The Pink Sheet Daily

Executive Summary

Management highlighted the ongoing growth potential of Humira and a late-stage pipeline that it says has the ability to generate between $4 billion and $6 billion of growth during the new pharmaceutical company’s first financial call with investors.

Advertisement

Related Content

Abbvie’s Elagolix Looks Set To Stake Claim In Endometriosis
Gilles Picard On Steering AbbVie Across Asia, the Middle East And Africa: An Interview With PharmAsia News (Part 2 of 2)
Gilles Picard On Steering AbbVie Across Asia, the Middle East And Africa: An Interview With PharmAsia News (Part 1 of 2)
Emerging Markets Earnings Roundup: Abbott, AbbVie, J&J And Novartis (Part 3)
No Near-Term Separations For Pfizer, But Business Model Will “Evolve”
The Street Assesses AbbVie
Abbvie: A Glimpse Of What The New Biopharma Will Look Like

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074838

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel